Search

372 Result(s)
Sort by

Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
The METAmorphosis

The METAmorphosis

At Boehringer Ingelheim’s META offices in the Middle East, Turkey and Africa all offices in the region are already free of single-use plastic.
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
NeO - smart and sustainable vaccines

NeO - smart and sustainable vaccines

The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Lyon

Lyon

The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
environmental sustainability commitments

environmental sustainability commitments

On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
Women in the workplace: Inspiring inclusion

Women in the workplace: Inspiring inclusion

On International Women’s Day, we address the critical role of women in our society and ensure their voice is heard at all levels of our organization.
More Health Overview

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Netherton Syndrome

Netherton Syndrome

Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Making more health through animal health

Making more health through animal health

Boehringer Ingelheim and Ashoka aim to build a world with a greater access to health for people, animals and their communities.
Rafał Rybicki

Rafał Rybicki

Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.